{"id":"W4365512324","doi":"10.1158/1538-7445.am2023-ct119","title":"Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <i>FGFR3</i> alterations (trial in progress)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fibroblast growth factor receptor; Hyperphosphatemia; Mucositis; Fibroblast growth factor receptor 1; Cancer; Internal medicine; Cancer research; Oncology; Fibroblast growth factor; Receptor; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001739634,0.002698824,0.002073022,0.0007008517,0.0006579875,0.00164195,0.001643604,0.00226914,0.00814046],"category_scores_gemma":[0.0008389002,0.0006183998,0.001277184,0.000648864,0.0009706315,0.001196151,0.0004248054,0.004916376,0.002300617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001232383,"about_ca_system_score_gemma":0.002537277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003026879,"about_ca_topic_score_gemma":0.005520562,"domain_scores_codex":[0.9995669,0.0001504011,0.00001950017,0.00008182724,0.000051209,0.0001300774],"domain_scores_gemma":[0.9993389,0.00008189701,0.000103162,0.00004825302,0.00005531519,0.0003724914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3973414,0.08410122,0.00573488,0.00312961,0.002032796,0.001371945,0.0006489748,0.006334494,0.2275555,0.001558681,0.05322948,0.2169612],"study_design_scores_gemma":[0.4685051,0.4855574,0.00943619,0.0001401595,0.0006260147,0.001559588,0.0001087019,0.002751466,0.01901347,0.0005141242,0.0117057,0.0000820754],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9510628,0.01107119,0.004001197,0.002190389,0.0005511869,0.007387751,0.01304555,0.001670394,0.009019538],"genre_scores_gemma":[0.951798,0.006469399,0.005370017,0.002557425,0.0002909381,0.004567484,0.01789322,0.0002505408,0.01080293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00814046,"threshold_uncertainty_score":0.02723259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03827723797424968,"score_gpt":0.4184666480959912,"score_spread":0.3801894101217415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}